Alchemi Wealth 13F Shows Increases in NVDA, TSLA

Alchemi Wealth filed a Form 13F with the SEC on May 7, 2026 that discloses equity positions held as of March 31, 2026, notably including positions in NVIDIA Corporation (NVDA) and Tesla, Inc. (TSLA), according to an Investing.com summary of the filing (May 7, 2026). The filing date places this disclosure well within the SEC's 45-day submission window for 13F managers and confirms Alchemi meets the regulatory $100 million threshold for required reporting. While 13F filings are backward-looking snapshots rather than blueprints for forward trading, the holdings mix and shifts disclosed can illuminate portfolio tilts, sector preferences, and risk appetite at the start of Q2 2026. This note examines the filing in context, drills into the regulatory and market implications, and offers a Fazen Markets perspective on what the reported positions imply for sector exposure and potential rebalancing risks.

Context

Form 13F filings are statutory disclosures required of institutional managers with investment discretion over at least $100 million in Section 13(f) securities; the filings report long equity positions as of the close of each calendar quarter. Alchemi's submission on May 7, 2026 covers holdings as of March 31, 2026, consistent with standard timing: the SEC gives managers up to 45 days after quarter end to submit their 13F (SEC Rule 13f-1(b)). The Investing.com summary published May 7 identifies NVDA and TSLA among Alchemi's reported positions, which is notable because both tickers have been the largest single-stock contributors to index volatility in 2025–26.

13F statements are inherently lagging: they disclose positions at quarter-end but not intraday trades, short positions, or derivatives exposure that can materially alter economic exposure after filing. That said, directional changes revealed in 13Fs—additions, trims, or new positions—remain useful for gauging manager conviction. Alchemi's May 7 filing should therefore be viewed as an input for triangulating manager behavior rather than a definitive statement about current holdings. For institutional investors monitoring crowding and concentration risk, the filing provides a measurable data point for the quarter ended March 31, 2026 (Investing.com; SEC 13F filings).

Finally, Alchemi's 13F arrives against a backdrop of elevated market concentration: the largest 10 S&P 500 constituents accounted for a higher share of market cap in early 2026 versus the same period in 2022. A small manager increasing exposure to names like NVDA and TSLA can contribute to crowding in already-heavy positions, a dynamic that institutional allocators monitor closely.

Data Deep Dive

The May 7, 2026 13F filing documents Alchemi's long equity holdings as of March 31, 2026; those securities are reported in accordance with SEC requirements and were summarized by Investing.com on the filing date. While the public summary lists NVDA and TSLA among disclosed positions, the 13F itself—filed with the SEC—remains the authoritative source for share counts and market values as of the quarter close. Institutional investors evaluating this filing should cross-reference the Investing.com summary with the raw SEC submission to confirm share quantities, market values, and the counting methodology used.

Because 13F reports exclude short positions and many derivatives, a manager's economic exposure to a given name can be materially different from the 13F long-only picture. For example, a hedged equity position using options or swaps would appear as a long equity holding while the offsetting synthetic short would not be visible in the 13F. Investors should therefore treat the Alchemi 13F as a partial view and seek additional disclosures or conversations where practical. The regulatory facts—filing date May 7, 2026 and quarter end March 31, 2026—allow timing-sensitive comparisons against price moves: NVDA and TSLA experienced notable intraday volatility in Q1 2026, which can amplify the P&L implications of any quarter-end position.

Comparative analysis is essential. If Alchemi's NVDA or TSLA weights materially exceed the median 13F manager's exposure reported for Q1 2026, that would indicate a concentrated active bet; if weights track the S&P 500 sector weights, it suggests a beta tilt rather than stock-specific conviction. Investors should compute these comparisons using the SEC filing data and market prices as of March 31, 2026 to ensure consistency.

Sector Implications

Alchemi's reported holdings in large-cap technology and EV names have implications beyond the one manager. NVDA and TSLA are both highly liquid but also highly influential at the sector and index level—NVDA for semiconductors and AI hardware, TSLA for EV and energy transition narrative. A pattern of concentrated positioning in these names across multiple 13F filers can lead to amplified sector flows and higher correlation among technology-related equities during risk-on episodes. Institutional allocators should therefore track not just single-firm filings but clusters of similar moves across filings in the same cycle.

For active managers, the crucial metric is not only absolute exposure to a stock but active share versus a chosen benchmark. If Alchemi’s allocation represents an overweight to technology vs the S&P 500 weight as of March 31, 2026, the manager is expressing a sector view that will perform relative to both systemic market drivers and idiosyncratic company outcomes. This nuance matters when portfolios are stress-tested under scenarios such as an AI hardware sell-off or supply-chain disruption for EVs.

At the index level, shifts among active managers towards NVDA and TSLA can increase tracking error for funds that are underweight these giants. Passive vehicles will continue to mechanically allocate by float-adjusted market cap, creating pressure in markets when active managers and passives accumulate the same names simultaneously. The May 7 filing therefore contributes one data point to broader monitoring of concentration risk in tech and EV sectors.

Risk Assessment

13F disclosures do not capture leverage, derivative overlays, or off-exchange transactions, which constrains their use as a sole risk metric. For risk managers, the key next steps after a 13F release are to assess directional concentration, cross-asset exposures, and liquidity risk under stressed market conditions. The timing of Alchemi's filing—within the SEC 45-day window—means reported shares reflect quarter-end marks that may have subsequently diverged materially in value as markets moved in April and early May 2026.

Liquidity risk is particularly pertinent for concentrated positions in names with episodic intraday volatility. NVDA and TSLA are generally liquid in normal market conditions, but correlated risk—such as sector rotation out of growth—can widen bid-ask spreads and impact execution costs for large trades. Institutional counterparties evaluating potential trades with Alchemi or similar managers should consider trade execution strategies that minimize market impact, including use of derivatives or block crossing networks where appropriate.

Another risk vector is regulatory and reputational: public disclosure of large positions invites scrutiny, and if a manager is perceived as crowded in a handful of names, counterparties and investors may demand higher transparency or more conservative risk controls. Allocators should therefore pair the 13F insight with conversations about governance, position-sizing rules, and stress-testing frameworks used by the manager.

Outlook

13F filings are backward-looking signals but remain a pragmatic tool for monitoring shifts in institutional positioning. Alchemi’s May 7, 2026 filing should prompt trackers to watch for follow-up indicators: SEC amendments, subsequent 13D/G filings if activist intent emerges, option-implied positioning from the options market, and intraday volume patterns that could suggest accumulation or distribution. If Alchemi maintains or increases exposure to NVDA and TSLA in subsequent filings, that pattern would affirm a durable conviction; conversely, rapid unwinds would be an early warning of de-risking behavior.

For broader markets, the concentration in a handful of names remains a structural theme. Managers and allocators should maintain scenario analyses that quantify portfolio sensitivity to a 20% move in NVDA or TSLA, given historical volatility regimes in 2025–26. This quantification helps in setting loss limits and in constructing hedges that are cost-effective and minimally dilutive to expected returns.

Institutional readers who want to track these dynamics in real time can use raw SEC 13F feeds and tools—our coverage at topic aggregates filings and highlights material changes across reporting cycles. Regular cross-referencing between public summaries (Investing.com, May 7, 2026) and primary SEC filings is essential to avoid misinterpretation.

Fazen Markets Perspective

From Fazen Markets' vantage point, Alchemi’s May 7, 2026 submission is best viewed as a tactical data point in a larger mosaic of positioning among active managers. A contrarian reading suggests that the crowding into NVDA and TSLA among multiple 13F filers creates asymmetric opportunity: if dislocations occur, liquidity providers and disciplined value-oriented allocators may find attractive entry points, whereas momentum-driven funds could face acute drawdowns. We see value in monitoring option-implied skew and notional exposure for these names as a real-time hedge effectiveness gauge.

Another non-obvious insight is that small-to-mid-sized managers like Alchemi can exert outsized informational influence when they increase positions in high-beta names simply because their trades, though smaller in absolute dollar terms than the largest asset managers, can signal a trend among active allocators. This signaling effect can become a self-fulfilling driver of short-term flows, especially in an environment where exchange-traded products and systematic strategies amplify directionality. Investors should therefore weigh 13F signals from smaller managers alongside those from the largest asset managers to separate idiosyncratic bets from systemic trends.

Finally, we recommend that allocators treat the May 7 disclosure as an invitation to engage rather than as a final verdict. Constructive dialogue with managers about position-sizing frameworks, use of derivatives, and intended holding periods will reduce informational asymmetry that 13F filings alone cannot resolve. For tools and aggregated filing data, users can consult our platform at topic for comparative analytics and cross-manager heat maps.

Bottom Line

Alchemi Wealth’s May 7, 2026 Form 13F discloses notable positions in NVDA and TSLA as of March 31, 2026; the filing is a backward-looking data point that should prompt comparative and liquidity-focused follow-up analysis. Institutional investors should cross-reference the SEC filing, monitor subsequent market signals, and engage managers directly to understand the drivers behind concentrated positions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.

FAQ

Q: Does the May 7, 2026 13F filing report Alchemi's short positions or derivatives exposure?

A: No. Form 13F only reports long positions in Section 13(f) securities as of the quarter end (March 31, 2026). Short positions, most derivatives, and off-exchange synthetic exposures are not disclosed in the 13F and therefore require supplementary sources or manager disclosures to assess fully.

Q: How should allocators compare Alchemi's 13F to peers?

A: Compare position weights using market values as of March 31, 2026, compute active share versus your chosen benchmark, and review concentration metrics (top 5–10 positions as a percentage of reported net assets). Also check subsequent trading data—option flows and intraday volumes—for signs of follow-through or unwinding.

Q: What are practical steps to manage crowding risk signaled by 13F filings?

A: Stress-test portfolios for 20% price moves in crowded names, assess liquidity under widened spread scenarios, and consider staggered execution strategies or hedges using options with defined costs. Engage managers on position limits and stop-loss protocols to reduce tail risk exposure.